pbsv_8k.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) May 31, 2023

 

Pharma-Bio Serv, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-50956

 

20-0653570

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

6 Road 696, Dorado, Puerto Rico

 

00646

(Address of Principal executive offices)

 

(Zip Code)

 

Registrant’s Telephone number, including area code (787) 278-2709 

                                                       

(Former name or former address, if changed since last report) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On May 31, 2023, Pharma-Bio Serv, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals and corresponding votes.

 

Irving Wiesen was elected as a Class I director by a plurality of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote. Mr. Wiesen shall serve as a Class I director until the 2026 Annual Meeting of Stockholders or until his successor is duly elected and qualified. The votes for this proposal were as follows:

 

Nominee

Votes For

Votes Withheld

Irving Wiesen

7,477,036

11,696,947

 

There were 515,852 broker non-votes on this proposal.

 

The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2023 received the following votes:

 

Votes For

Votes Against

Abstain

14,344,226

1,492,688

3,852,921

 

There were no broker non-votes on this proposal.

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

PHARMA-BIO SERV, INC.

 

 

 

 

 

Date: May 31, 2023

By:  

/s/ Pedro J. Lasanta

 

 

 

Pedro J. Lasanta  

 

 

 

Chief Financial Officer, Vice President Finance and Administration and Secretary

 

 

 
3